People with type 2 diabetes, particularly those diagnosed at a young age, can face an extended wait for medication to treat cardiovascular risk factors, even if they are in a high-risk category, research shows.
Geographic remoteness is strongly associated with a reduced likelihood of being prescribed the most recent classes of glucose-lowering medications, find Australian researchers.
People with type 2 diabetes, especially young people, do not receive treatment for hypertension and dyslipidemia in a timely manner, even when they have high cardiovascular risk, study results show.
06-16-2020 | ADA 2020 | Conference coverage | News
Healthcare providers can remain slow to intensify type 2 diabetes medication even after making the jump to basal insulin, with consequences for glycemic control and potentially cardiovascular risk, study results show.
Adults who develop type 2 diabetes at a younger age have a much lower likelihood of achieving glycemic control a year after diagnosis than those who develop it in middle age, research indicates.
Although helpful for primary care physicians, a type 2 diabetes treatment decision support tool may be missing the point for most people with poorly controlled glucose levels, suggest findings from a pilot study.
US researchers report a decrease in the use of key indicators of comprehensive diabetes care in the year following a cancer diagnosis among people with diabetes.
A reassuring UK study has found limited evidence to suggest non-White patients are at a disadvantage for being diagnosed with type 2 diabetes in primary care and having their cardiometabolic risk managed around the time of initial diagnosis.